Neurologic Imaging

What Is the Best Initial Imaging for Lumbosacral Plexopathy with Known Malignancy?

·
What Is the Best Initial Imaging for Lumbosacral Plexopathy with Known Malignancy?

A 68-year-old patient with a history of prostate cancer, treated with external beam radiation therapy two years ago, presents to your clinic with three months of progressive right leg weakness and a deep, aching pain in his buttock and thigh. His neurologic exam confirms weakness in an L5-S1 distribution. You suspect a lumbosacral plexopathy, but the critical question is the cause: is this a recurrence of his malignancy infiltrating the nerve plexus, or is it a delayed effect of his radiation treatment? This distinction will fundamentally alter his prognosis and management. This article details the American College of Radiology (ACR) evidence-based workflow for this specific scenario. For initial imaging, the ACR finds that MRI lumbosacral plexus without and with IV contrast is Usually Appropriate.

Who Fits This Clinical Scenario for Lumbosacral Plexopathy?

This imaging workflow is designed for a specific patient population: those presenting with signs and symptoms of lumbosacral plexopathy who have a known history of malignancy or have undergone treatment, particularly radiation therapy, that could affect the plexus. The typical presentation includes unilateral or asymmetric lower extremity pain, weakness, numbness, or paresthesias that do not follow a simple dermatomal or myotomal pattern.

Inclusion Criteria:

  • Symptoms localizing to the lumbosacral plexus (e.g., pain in the hip, buttock, or leg; weakness in multiple muscle groups like foot drop with weak hip flexion).
  • A documented history of malignancy, especially pelvic tumors such as colorectal, prostate, cervical, uterine, or bladder cancer, as well as lymphoma or sarcoma.
  • A history of radiation therapy to the pelvis, abdomen, or lumbosacral spine.

Exclusion Criteria (These patients follow different guidelines):

  • No Malignancy History: If the patient has no history of cancer or radiation and presents with similar symptoms, they fit the nontraumatic lumbosacral plexopathy without known malignancy scenario, which has a different pre-test probability for various causes.
  • Acute Trauma: If the symptoms began after a significant traumatic event like a pelvic fracture or major fall, the workup follows the traumatic plexopathy guidelines, where concerns for hematoma or direct nerve transection are higher.
  • Upper Extremity Symptoms: If the symptoms involve the arm, shoulder, or hand, the evaluation should follow the guidelines for brachial plexopathy.

What Diagnoses Are You Working Up in This Malignancy-Related Plexopathy Scenario?

The primary goal of imaging in this context is to differentiate between direct tumor involvement and the consequences of cancer treatment, as their management pathways are starkly different. The differential diagnosis drives the choice of imaging modality.

Malignant Plexopathy (Tumor Recurrence or Infiltration)
This is often the most pressing concern. Recurrent or metastatic disease can directly invade the nerves of the lumbosacral plexus or compress them via an adjacent soft tissue or bony mass. Clinically, this often presents with severe, unrelenting pain that may precede motor or sensory deficits. Identifying a discrete, enhancing mass is the key to this diagnosis.

Radiation-Induced Lumbosacral Plexopathy (RILP)
A challenging diagnosis of exclusion, RILP is a delayed complication of radiation therapy, typically occurring months to many years after treatment. It results from microvascular damage and subsequent fibrosis of the nerves and surrounding tissues. The classic presentation is a progressive, often painless, lower motor neuron weakness. Imaging may show diffuse nerve thickening and enhancement, but typically lacks a discrete mass.

Post-Surgical Plexopathy
In patients who have undergone pelvic surgery, direct nerve injury, post-operative hematoma, or scar tissue (fibrosis) can lead to plexopathy. The timing of symptom onset relative to the surgery is a crucial clinical clue. Imaging helps identify fluid collections, abscesses, or extensive scarring that may be amenable to intervention.

Metastatic Disease to Bone
Metastases to the sacrum, iliac bones, or lumbar spine can compress the nerve roots as they exit the neural foramina to form the plexus. This can clinically mimic a true plexopathy. While the primary pathology is osseous, the neurologic symptoms are from secondary nerve compression.

Why Is MRI of the Lumbosacral Plexus with and without Contrast Usually Appropriate?

The ACR designates MRI lumbosacral plexus without and with IV contrast as Usually Appropriate because it provides the highest diagnostic yield for the key differential diagnoses in this scenario. It directly visualizes the nerves of the plexus and the surrounding soft tissues with unparalleled detail, all without using ionizing radiation (0 mSv).

The rationale for this specific protocol involves leveraging the strengths of both the pre- and post-contrast sequences:

  • Without IV Contrast: Non-contrast sequences, particularly T1-weighted and fluid-sensitive sequences like STIR (Short Tau Inversion Recovery), are essential. T1 imaging is excellent for evaluating the normal fat planes surrounding the plexus; obliteration of these planes can be an early sign of tumor infiltration. STIR sequences are highly sensitive for detecting nerve edema and signal abnormality, which can be seen in both tumor infiltration and radiation-induced changes. They are also critical for identifying muscle denervation changes, which confirm the chronicity and distribution of nerve injury.
  • With IV Contrast: The administration of gadolinium-based contrast is the critical step for differentiating the most likely causes. Recurrent tumor typically appears as a discrete, avidly enhancing mass. In contrast, radiation-induced fibrosis often shows more diffuse, linear, or sheet-like enhancement that is less intense than a tumor. While there is overlap, the pattern of enhancement is a powerful diagnostic clue.

Why are other studies rated lower for this initial workup?

  • FDG-PET/CT whole body is rated May be appropriate. While it is highly sensitive for metabolically active tumor recurrence and can be valuable for staging, it has lower spatial resolution than MRI for defining the precise relationship between a tumor and the individual nerves of the plexus. It is often a valuable downstream or problem-solving tool but is not the ideal first-line anatomic study. It also involves significant radiation exposure (☢☢☢☢ 10-30 mSv).
  • CT abdomen and pelvis with IV contrast is also rated May be appropriate. CT is excellent for detecting bony destruction from metastases and identifying large soft tissue masses. However, its ability to directly visualize the nerves of the plexus and differentiate tumor from post-radiation fibrosis is substantially inferior to MRI. It is a reasonable alternative if MRI is contraindicated but should not be the first choice.

What’s Next After MRI of the Lumbosacral Plexus? Downstream Workflow

The results of the MRI will guide the subsequent clinical pathway. The report should be interpreted in close correlation with the patient’s history, symptoms, and prior treatment fields.

If the MRI is positive for a discrete, enhancing mass suggestive of tumor recurrence:
The next step is typically a tissue diagnosis. An image-guided (often CT-guided) biopsy of the mass is required to confirm malignancy before initiating oncologic treatment, such as further radiation, chemotherapy, or targeted therapy. Surgical consultation may also be warranted to assess for potential resection, though this is often challenging in the setting of recurrence.

If the MRI is negative for a discrete mass but shows diffuse nerve thickening or enhancement consistent with radiation-induced plexopathy:
This becomes a diagnosis of exclusion. The primary goal is symptom management, including physical therapy to maintain function and neuropathic pain management. There are no curative treatments for RILP. It is crucial to rule out other causes, and sometimes FDG-PET/CT may be used to confirm the absence of metabolic activity suggestive of a tumor.

If the MRI is indeterminate or equivocal:
This is a common and challenging situation. Findings may include subtle enhancement or soft tissue thickening that does not clearly fit either tumor or radiation fibrosis. In these cases, a multidisciplinary discussion involving radiology, oncology, and neurology is vital. Short-interval follow-up MRI (e.g., in 3 months) to assess for change, or proceeding to FDG-PET/CT to evaluate for metabolic activity, are both reasonable strategies.

Pitfalls to Avoid (and When to Get Help)

Navigating this diagnostic challenge requires careful planning to avoid common errors that can delay diagnosis or lead to incorrect conclusions.

  • Ordering the Wrong MRI: Requesting an “MRI of the lumbar spine” is a frequent pitfall. While this may show the nerve roots, it does not include the dedicated, high-resolution sequences needed to visualize the plexus itself as it courses through the pelvis. Be specific: order an “MRI of the lumbosacral plexus.”
  • Omitting Contrast: Ordering a non-contrast MRI saves time but critically limits the ability to differentiate tumor from post-treatment effects. Unless the patient has a severe contraindication, contrast is essential.
  • Misinterpreting Fibrosis: Post-treatment scar and fibrosis can enhance, sometimes mimicking a tumor. Relying solely on the presence of enhancement is insufficient; the pattern (nodular vs. diffuse) and clinical context are key.
  • Confirmation Bias: Do not assume plexopathy is the only cause. The MRI should be carefully reviewed for other potential mimics, such as sacral stress fractures (common after radiation) or vascular pathology.

If the imaging findings are ambiguous or conflict with the clinical picture, escalate by requesting a multidisciplinary tumor board review or a direct consultation with a neuroradiologist.

Related ACR Topics and Tools

For a comprehensive overview of imaging for all types of plexopathy, including traumatic and non-malignant causes, refer to our parent guide. For specific technical details or to explore adjacent clinical scenarios, the following resources are available.

Frequently Asked Questions

Why not start with a PET/CT if I’m most worried about cancer recurrence?

While FDG-PET/CT is excellent for detecting metabolically active tumors, MRI provides superior anatomic detail of the nerves and surrounding soft tissues. The ACR recommends MRI as the initial study to precisely define the extent of disease and its relationship to the plexus, which is critical for treatment planning (e.g., biopsy or radiation fields). PET/CT is often used as a second-line or problem-solving tool if the MRI is equivocal or for systemic staging.

My patient has a pacemaker and cannot get an MRI. What is the best alternative?

If MRI is absolutely contraindicated, the next best study is CT abdomen and pelvis with IV contrast, which the ACR rates as ‘May be appropriate.’ While less sensitive for direct nerve visualization, it can identify large soft tissue masses, bony destruction from metastases, and lymphadenopathy. In some cases, FDG-PET/CT may also be considered to assess for metabolic activity, though it also involves a CT component.

How long after radiation therapy can radiation-induced lumbosacral plexopathy (RILP) occur?

RILP is a delayed effect, and the latency is highly variable. It can occur as early as a few months after treatment but most commonly presents between 1 and 5 years post-radiation. However, cases have been reported developing 20 years or more after therapy, so it should remain on the differential even long after treatment is completed.

The MRI report is equivocal. What is the most useful next step?

When an MRI is indeterminate, the best next step is a multidisciplinary discussion. If there is a subtle finding that could represent an early recurrence, a short-interval follow-up MRI in 2-3 months can assess for change. Alternatively, an FDG-PET/CT can be performed to see if the area of concern is metabolically active, which would strongly favor tumor over benign fibrosis. A targeted biopsy may be considered if a safe access route exists.

Does chemotherapy cause plexopathy?

While chemotherapy is a well-known cause of peripheral neuropathy, it typically presents as a symmetric, length-dependent ‘stocking-glove’ sensory loss. It is an uncommon cause of a focal, asymmetric process like a true plexopathy. However, in a patient with a history of both chemotherapy and radiation, untangling the contribution of each can be difficult, but imaging is primarily directed at the structural causes (tumor, fibrosis) that can be visualized.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026